The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.After the release of the top-line results from its phase 2 clinical trial of its lead drug candidate, VK2735 (oral formulation), in August, there were investors who doubted whether Viking Therapeutics (VKTX 1.37%) had a bright future. But a closer look suggests there are strong reasons to believe the recovery in the stock price since then is justified. Here's why.Vikings Therapeutics in 2025The co ...